Core Viewpoint - Baiyang Pharmaceutical (301015.SZ) announced a plan for its controlling shareholder, Baiyang Pharmaceutical Group Co., Ltd., to reduce its shareholding by up to 15,768,585 shares, representing 3.00% of the total share capital, due to personal funding needs [1] Group 1: Shareholding and Reduction Plan - The controlling shareholder holds 369,077,400 shares, accounting for 70.22% of the total share capital [1] - The planned reduction will occur within three months after a 15 trading day period from the announcement date [1] Group 2: Pledged Shares - As of the announcement date, the controlling shareholder has pledged 173,674,652 shares, which is 47.06% of its holdings and 33.04% of the total share capital [1] - Together with its concerted parties, a total of 192,254,652 shares are pledged, representing 47.27% of the controlling shareholder's holdings and 36.58% of the total share capital [1] Group 3: Fundraising and Financial Details - Baiyang Pharmaceutical's IPO raised a net amount of 343 million yuan after deducting issuance costs, with a total fundraising target of 702 million yuan [3] - The company plans to use the funds for various projects, including a modern logistics distribution center and e-commerce operations [3] - The total amount raised from the IPO and convertible bonds is 1.262 billion yuan [5]
百洋医药控股股东拟减持 36%总股本质押A股募12.6亿